CancerVax Unveils Polyepitope Smart mRNA Platform That Disguises Cancer as Multiple Viral Infections, Achieving 99.5% Global Population Coverage
核心洞察
CancerVax has completed design and in-vitro validation of a single Polyepitope Smart mRNA (搜索) that disguises cancer cells as multiple viral infections to activate pre-existing T-cell immunity.
The Version 2 construct encodes viral epitopes from measles, influenza, CMV, and others, achieving 99.50% global population coverage based on AI-assisted computational analysis.
The platform uses a Smart mRNA that activates selectively in cancer cells, instructing them to produce viral proteins that "trick" the immune system into recognizing and killing them.
Lehi, Utah-based CancerVax, Inc. announced on July 14, 2026 that it has successfully developed a single Polyepitope Smart mRNA (搜索) capable of disguising cancer cells as multiple viral infections simultaneously, a milestone the company describes as a significant step toward a universal cancer immunotherapy platform.
The platform's core innovation lies in a Smart mRNA construct that activates selectively within cancer cells. Once activated, the mRNA instructs cancer cells to produce proteins associated with viruses that are highly prevalent in the human population. This effectively disguises cancer cells as familiar viral infections, "tricking" the body's immune system into recognizing and killing them with precision.
From Single Epitopes to a Polyepitope Strategy
Dr. George Katibah, Chief Scientific Officer at CancerVax, explained the evolution of the company's approach. "Our earlier work focused on individual viral epitopes, such as measles," Dr. Katibah said. "With our Polyepitope Smart mRNA (搜索) design, we have expanded that concept by encoding multiple viral epitopes with broad population immunity, including measles, influenza, CMV and others, into a single mRNA construct."
The rationale behind the polyepitope strategy is to increase the probability that a given patient's existing T-cell immunity will recognize at least one of the encoded viral signals and mount an immune response against the cancer cell. The company's recent in vitro results, Dr. Katibah noted, "provide encouraging validation of this strategy and represent an important step toward a broadly applicable cancer immunotherapy platform."
AI-Assisted Design and Population Coverage
Dr. Adam Grant, Principal Scientist at CancerVax, detailed the computational methodology behind the construct's design. "Using large-scale immune epitope datasets and AI-assisted analysis, we identified and combined the most viable viral epitopes for our design to maximize the broadest population coverage," Dr. Grant said. "With every epitope we add, we increase the likelihood of activating existing T-cells. However, given the physical size constraints of practical mRNA design, we had to be selective."
The iterative design process yielded progressively broader coverage. Version 1 of the Polyepitope Smart mRNA (搜索) achieved a global population coverage of 96.26%. Following expansion of the underlying dataset, the team generated Version 2, which reached 99.50% population coverage. "This is truly a one of a kind mRNA design and we believe this broad and universal approach will be the winner we take to the clinic," Dr. Grant added.
Path Toward the Clinic
CancerVax's platform represents a novel approach within the cancer immunotherapy landscape, leveraging pre-existing immunity rather than engineering new immune responses de novo. By harnessing T-cell memory against common viral pathogens that the vast majority of the global population has already encountered, the platform aims to redirect existing immune surveillance toward malignant cells. The company has indicated its intention to advance this polyepitope design into clinical development.